Cohort-based protocol outcomes for GLP-1 and peptide compound combinations.
Each case study summarizes aggregated outcomes from opted-in Halflife users running specific compound combinations. Reports include cohort size, observation window, adherence rates, and measured outcome metrics. All data is anonymised and aggregated — no individual user records are identifiable.
Tirzepatide + BPC-157: Body Recomposition — 20-Week Observational Window
Aggregated weight change, lean mass preservation indicators, and recovery markers from opted-in users running tirzepatide 7.5–10 mg weekly alongside BPC-157 250 mcg twice daily. Currently at Week 4 of a 20-week observational window.
Testosterone Cypionate + CJC-1295 / Ipamorelin: Lean Mass Protocol — 16-Week Observational Window
Adherence data and self-reported lean mass outcomes from opted-in users running testosterone cypionate 150 mg/week alongside CJC-1295 no-DAC + ipamorelin pre-bed dosing. Currently at Week 4 of a 16-week observational window.
NAD+ + Epitalon Longevity Cycle: Adherence and Cycle Completion — 12-Month Observational Window
Cycle length, completion rates, and cycling frequency from opted-in users running NAD+ injectable plus Epitalon. Self-reported energy and sleep quality included as secondary metrics. Currently at Week 4 of a 12-month observational window — cycle data accumulating.
Tirzepatide vs. Semaglutide: Real-World Adherence — 12-Week Observational Window
Comparative adherence analysis between opted-in tirzepatide and semaglutide users. Tracking dose escalation timing, dropout patterns, side effect frequency, and time to steady-state dosing. Currently at Week 4 of a 12-week observational window.
How Halflife Labs collects and aggregates protocol outcome data.
All data is collected from Halflife app users who explicitly opt in to contribute anonymised protocol data to research. Opt-in is disabled by default and can be revoked at any time.
Data is aggregated at the cohort level. Each case study defines a cohort by compound combination, dosing range, and minimum observation window. Individual records are never published or shared.
All studies are observational, non-interventional, and retrospective. Halflife does not assign protocols, control dosing, or influence user behavior. Outcome metrics are derived from self-reported injection logs and weight entries.
Access aggregated protocol data for research, integration, or licensing.
Halflife Labs provides structured access to anonymised, aggregated protocol outcome data for academic researchers, telehealth platforms, and pharmaceutical companies. All access models are IRB-compatible and follow opt-in consent frameworks.
Anonymised dataset access and IRB partnership framework for publishable studies on GLP-1 and peptide protocol outcomes.
API-first protocol tracking and adherence monitoring integration for patient portals.
Longitudinal real-world evidence datasets for pharmaceutical companies and market research firms.